



CLX Investment Company, Inc.

(OTC BB: CLXN)

29970 Technology Drive, Suite 203, Murrieta, CA 92563

Telephone: (951) 677-6735 / Facsimile: (951) 677-6573

investors@clxinvestments.com

www.clxinvestments.com

March 2008 Newsletter

CLX Investment Company Plans Pre-Clinical Trials Validation Study on Zonda's Rapid Point of Care Test for Chlamydia

Study will be used to perfect clinical trials protocol

CLX Investment Company (stock symbol - OTC BB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced that the company is scheduled to begin a validation study for Zonda's rapid point of care test for chlamydia in preparation for upcoming clinical trials.

Zonda is currently reviewing virology laboratories as candidates to conduct the study, which is expected to take approximately four weeks. The purpose of the study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.

"We are taking all of the steps necessary to ensure that our clinical trials are done correctly and that that we maintain the highest level of integrity throughout this process," stated Vera Leonard, chief executive officer of Zonda and CLX. "The market potential of Zonda's rapid point of care test for chlamydia, assuming it receives FDA clearance and CLIA waiver, is so significant that we want to make certain that all of our procedures are conducted correctly.

"There is no lack of confidence in the product by management and we look forward to beginning both the validation study and, shortly thereafter, the clinical trials," Ms. Leonard added.

In addition to their use in preparation for the clinical trials, results from the validation study may be helpful in other applications, such as in overseas markets where additional clinical data can support the sales of the product s currently in the market. CLX may also pursue a strategic alliance relationship with an established company in

(continued on page 4)

1 in 4 Teenage Girls Has a Sexually Transmitted Disease, Says CDC

A new study presented by the U.S. Center of Disease Control (CDC) at a recent STD prevention Conference estimates that one in four young women between the ages of 14 and 19 in the United States – or 3.2 million teenage girls – is infected with at least one of the most common sexually transmitted diseases, which includes chlamydia.

The results, which were based on data from 2003-04, showed that nearly one-half of African-American teenage girls were infected with at least one STD.

The CDC currently recommends annual chlamydia screening for sexually active women under the age of 25.

The press release regarding the study can be found at <http://www.cdc.gov/stdconference/2008/media/release-11march2008.htm>

Inside This Issue

Greeting from CEO Vera Leonard
Page 2

CRO Selected for Upcoming Clinical Trials on Zonda Chlamydia Test
Page 2

Form 4 Filed on Common Stock Acquisition
Page 2

CEO Interview Posted to Company Website
Page 3

Sentry Logisitics Engaged for Storage of Zonda Chlamydia Tests
Page 4

About the Company

CLX Investment Company, Inc. (OTC BB: CLXN) is a holding company seeking to provide long-term value for its shareholders by executing an acquisition strategy in the medical diagnostic testing field.

CLX owns a 51% equity interest in Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. The Company has announced a plan to acquire the remaining 49% of Zonda and plans to make this subsidiary a significant focus of CLX's operations.

CLX also holds a common stock position in ActionView International, Inc. a publicly traded company that designs, develops, and manufactures vividly illuminated motion billboards.

For more information, please visit the CLX website at www.clxinvestments.com.

Contract Research Organization (CRO) Selected for Clinical Trials on Zonda's Rapid Point of Care Test for Chlamydia

CLX Investment Company, Inc. has announced that the company has selected Trial Care International, LLC (TCI) to serve as Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.

Trial Care International, LLC specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients.

Trial Care International offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting.



Safis Solutions assisted with selection of Trial Care International through a process that began with a request for proposal from several CROs. Two finalists were then identified to make detailed presentations, and Trial Care International was

ultimately selected to serve as CRO.

Safis Solutions (www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (<http://www.ahpartners.com/>), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations.

Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.



(continued on page 3)

Greetings from the CEO

The period since the publication of our last newsletter has been an eventful time for CLX, as we completed several very important steps in the process of preparing for clinical trials for Zonda's rapid point of care test for chlamydia.



First, we retained Sentry Logistic Solutions to provide temperature-controlled storage and third party logistics for the chlamydia tests that will be used in the clinical trials. Then, Trial Care International was engaged to serve as Contract Research Organization (CRO) for the trials.

Last week, we were pleased to announce an upcoming validation study for the chlamydia tests. We expect that study to not only confirm that our testing protocol includes all the information needed for proper implementation, but it may also provide critical information that can be used in other applications. These may include overseas markets where additional clinical data can support the sales of the products currently in the market and to perhaps pursue a strategic alliance relationship with an established company in the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process.

In addition to this recent activity, we expect the next several weeks to hold even more significant announcements regarding the current activities and future direction of CLX, and we hope that shareholders continue to closely monitor our progress.

Best regards,

Vera Leonard, Chief Executive Officer

CLX CEO Files Form 4 on Acquisition of Common Stock

CLX CEO Vera Leonard has acquired 5 million shares of CLX common stock, bringing her total common stock position to 10 million shares. The 5 million shares were granted as part of Ms. Leonard's compensation package for accepting the CEO position with CLX.

"Ms. Leonard, in a relatively short time, has prepared Zonda and its chlamydia test for the upcoming scheduled clinical trials, and we are pleased to include this additional share position as part of her compensation package as CEO of CLX," stated Robert McCoy, chairman of CLX Investment Company. "Ms. Leonard has done an excellent job leading both CLX and Zonda thus far, and the Board is highly confident in her ability to deliver value to CLX shareholders. As CLX and its subsidiary operations reach identifiable milestones and achievements, the Board intends to provide additional opportunities for Ms. Leonard to increase her share position as part of her compensation."

It was also reported that Pat Edgerton, a member of the company's Board of Directors, has filed a Form 4 reporting two stock acquisition transactions for Mr. Edgerton. As a result of acquiring these shares, the Form 4 reports that Mr. Edgerton now holds 13,791,666 shares of CLX common stock.

Forward-Looking Statements

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Interview with Vera Leonard Posted to Company Website and EquityDigest.com

Written Question and Answer Feature Includes Estimate of a \$500 Million Potential Market for Zonda's Chlamydia Testing Product

CLX Investment Company, Inc. announced that Vera Leonard, chief executive officer of Zonda and CLX, has participated in a question and answer feature that has been posted to the CLX website at <http://www.clxinvestments.com/othermedia.php>. The transcript will also be added to the company's profile on www.equitydigest.com in the coming days. The question and answer feature includes a detailed discussion by Ms. Leonard of the estimated market potential for Zonda's rapid point of care diagnostic test for chlamydia. CLX and Zonda are currently preparing to initiate clinical trials for the HandiLab-C test for Chlamydia as part of the process to achieve FDA clearance for the product.

Ms. Leonard reviews the fact that chlamydia is now the most frequently reported sexually transmitted disease (STD) in the United States, with more than one million cases reported to the U.S. Centers for Disease Control in 2006. As a result, the CDC has updated its guidelines to recommend that all sexually active females aged 26 or younger be tested annually for chlamydia. With U.S. Census estimates of over 30 million females between the ages of 15 and 29, Ms. Leonard observes that this represents a huge market for chlamydia testing technologies.

Despite the tremendous need, Ms. Leonard continues in the question and answer feature to point out that there is not a technology or testing device currently available that allows doctors to screen patients in a rapid, cost effective and reliable manner. The company's research estimates that as much as 70% of this target population is being missed, which makes the market for the HandiLab-C not only large, but also hugely underserved.

Ms. Leonard also points out that chlamydia testing procedures currently in use require various techniques from heating the specimen for 10 minutes to repeated steps of squeezing and twisting the swab against the side of the test tube. Some products have as many as 11 steps in the testing process. By comparison, the HandiLab-C test for Chlamydia is an enzyme-based technology. There are no antigens to extract. Instead the process is simple, 2-step, self-contained and complete in 15 minutes or less.

Ms. Leonard also discusses the fact that Zonda's chlamydia test is designed to be used in a doctor's office, providing additional incentive for its widespread use. First, there is the advantage that with an almost immediate result, the patient is there to allow the doctor to provide counseling and begin treatment immediately. A lab test can take several days for the test result to be reported. Second, she points out that when a doctor sends a sample to a lab for chlamydia testing, the doctor does not receive the reimbursement from the insurance company, the lab does. With HandiLab, any reimbursement will be made to the doctor, allowing the doctor to bring greater revenue into his or her practice while utilizing a test that allows the patient to be tested and treated in the same visit.

The logo for EquityDigest.com, featuring the word "Equity" in black and "Digest" in green, with ".com" in a smaller black font to the right.

Ms. Leonard concludes the session with an estimate of the potential U.S. market for the HandiLab-C based on an expected price to patients of \$17 - \$18 per test. Given the number of females in the age range recommended for testing under CDC guidelines, the potential U.S. market for the test would be in excess of \$500 million.

"I was pleased to have this opportunity to address some of the major reasons why CLX Investment Company has focused its attention on Zonda's chlamydia product," commented Ms. Leonard. "This would be by no means a product of only minor significance in the STD testing market. Given the realities of the growing chlamydia problem in the U.S., particularly the tremendous shortfall in screening for this disease, it is very easy to see how an FDA cleared chlamydia testing product that is simple enough to be used in a doctor's office would likely capture a very large share of the chlamydia testing market."

"I hope this Q & A feature will be helpful for CLX shareholders and provides an understanding of why we are so excited by the potential of Zonda's chlamydia testing product. We expect this to be the first of a series of interviews that will allow me to directly address our motivations and any progress that we can report on the process of launching the HandiLab-C in the U.S. and other worldwide markets," Ms. Leonard added.

Trial Care International Selected as Contract Research Organization (CRO) Selected for Zonda's Clinical Trials

(continued from page 2)

"We are pleased to have identified Trial Care International as the CRO for Zonda's clinical trials and look forward to their support and expertise. Having the services of a top quality CRO is a crucial element in clinical trial management," stated Vera Leonard, chief executive officer of Zonda and CLX Investment Company.

"This is a big step forward in the process of bringing this important product to the market. We believe Trial Care International is the ideal partner to assist us as we navigate this process," Ms. Leonard added.

Sentry Logistic Solutions Engaged to Ensure Secure Storage of Zonda Chlamydia Tests with in Preparation for Clinical Trials

In preparation for planned clinical trials for Zonda's rapid point of care test for Chlamydia, CLX Investment Company recently announced that the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions ("Sentry"), a leading provider of temperature-controlled storage and third party logistics.

Sentry offers refrigerated, ambient, frozen and ultra low storage, logistics and distribution services for a broad range of clinical and commercial biopharmaceutical materials and components. Its experienced staff and 53,000 square-foot facility can handle virtually any storage need and enhance a client's supply chain capabilities.

In anticipation of the initiation of clinical trials scheduled for the mid- to late-1st calendar quarter of 2008, Sentry has received a sufficient supply of Chlamydia tests in bulk and will disseminate them for use in the trials as appropriate. Sentry will also provide additional services related to the storage and distribution of the tests including cold chain logistics, labeling and packaging.



For additional details regarding Sentry's capabilities and services, please visit <http://www.sentrylogistic.com/services.php>.

"We are pleased to have Sentry Logistic Solutions involved with the scheduled clinical trials for the Zonda Chlamydia test," said Vera Leonard, chief executive officer of Zonda and CLX. "Sentry has the facilities and the resources necessary to ensure that the Chlamydia tests are properly stored, labeled and distributed before and during the trials. We look forward to establishing a good working relationship with Sentry as we position CLX to potentially acquire, license and/or distribute additional medical diagnostic testing products."

Zonda Plans Pre-Clinical Trials Validation Study

(continued from page 1)

the U.S. medical diagnostic testing market to provide resources and assistance through the clinical trials and FDA clearance application process, and the validation study may help to secure such a relationship. Safis Solutions is assisting Zonda in the process of selecting a laboratory for the validation study. Safis Solutions (www.safis-solutions.com), is an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide.

Pavel Holik Appointed as New Director of Commercial Operations for Zonda, Inc. Subsidiary

Mr. Holik to Work Out of New Dallas Offices

CLX Investment Company, Inc. has announced that Zonda's Director of European Sales, Pavel Holik, has been promoted to the position of Director of Commercial Operations and has relocated to the new Dallas offices. This position, which is inclusive of the duties of Mr. Holik's previous title, will also include business analysis, strategic planning, worldwide distribution, and oversight of manufacturing.

The new offices, which are located in the North Dallas Business Corridor on Preston Road, will house the primary business operations of Zonda, including the office of Vera Leonard, president and chief executive officer of both Zonda and CLX Investment Company.

"We are pleased to have established our new Dallas offices as Zonda's primary corporate location," stated Ms. Leonard.

"This location is ideal for a number of reasons. We expect that these offices will allow us to effectively handle the future growth of Zonda as it plans for the expected launch of Zonda's Chlamydia product in the U.S. We will also use these offices to coordinate efforts to evaluate additional products and technologies for CLX to become involved with," she added.

As CLX considers additional medical diagnostic products and technologies that may be acquired and/or licensed, Mr. Holik may be utilized for these initiatives as well. Mr. Holik has worked with Zonda since late 2005 and was announced as the company's Director of European Sales in February 2006. His focus was on the establishment of distributor relationships in markets across Europe.

"Mr. Pavel Holik has proven himself to be an outstanding asset to Zonda through his work with the company's European distributors, and we are extremely confident that he will bring this same level of effectiveness to his new responsibilities," commented Ms. Leonard.

"We are pleased that Pavel has made such a serious commitment to our efforts by moving his family to Dallas to work with us in Zonda's new corporate headquarters. His assistance will be a significant benefit to management as we implement our growth strategies for both CLX and Zonda," Ms. Leonard added.

Mr. Holik previously served as product manager and business analyst for a leading provider of electronic voting solutions. As general manager for a Czech airplane manufacturer, Mr. Holik established a North American sales and customer support office, negotiated exclusive sales and distribution contracts, and worked closely with investors and venture capital groups to grow the company. Before being assigned to establish the airline's North American office, Mr. Holik served as director of sales, aircraft sales manager and aircraft salesperson.